On July 10th, the National Healthcare Security Administration announced the "2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and Commercial Health Insurance Innovative Drug Catalog Adjustment Work Plan", clarifying that the adjustment of the 2025 Basic Medical Insurance Drug Catalog and the formulation of the Commercial Health Insurance Innovative Drug Catalog will be carried out simultaneously. This year, the National Healthcare Security Administration will formulate for the first time a list of innovative drugs for commercial health insurance. The plan is clear that the list of innovative drugs in commercial insurance mainly includes innovative drugs that exceed the basic positioning of insurance, cannot be included in the basic list temporarily, but have high innovation level, great clinical value, and significant patient benefits. It is recommended to refer to multi-level medical security systems such as commercial health insurance and medical mutual assistance. New generic drugs approved for market by the national drug regulatory department from January 1, 2020 to June 30 this year, as well as exclusive drugs such as rare disease treatment drugs approved for market by the national drug regulatory department before June 30 this year, can be separately declared for the commercial insurance innovative drug catalog or simultaneously declared for the commercial insurance innovative drug catalog and basic catalog. (New Society)